Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(Z)-Orantinib ((Z)-SU6668) 是一种有效,选择性,具有口服活性和 ATP 竞争性的 Flk‐1/KDR,PDGFRβ和 FGFR1抑制剂,IC50值分别为 2.1,0.008 和 1.2 μM。(Z)-Orantinib 是有效的抗血管生成和抗肿瘤剂,可诱导已形成的肿瘤消退。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 194 | 5日内发货 | ||
5 mg | ¥ 297 | 5日内发货 | ||
10 mg | ¥ 497 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 5日内发货 |
(Z)-Orantinib 的其他形式现货产品:
产品描述 | (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC 50 s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces established tumor regression[1] [2]. |
体外活性 | SU6668 (5-15 min) inhibits Flk-1 trans-phosphorylation (K i =2.1 μM), FGFR1 trans-phosphorylation (K i =1.2 μM), and PDGFR autophosphorylation (K i =0.008 μM) [1]. SU6668 (0.03-10 μM; 60 min) inhibits the VEGF-stimulated increase of KDR tyrosine phosphorylation in HUVECs [1]. SU6668 inhibits HUVECs mitogenesis induced by both VEGF and FGF in a dose-dependent manner with IC 50 s of 0.34 and 9.6 μM, respectively [1]. |
体内活性 | SU6668 (4-200 mg/kg/day; p.o. for 21 d) induces dose-dependent inhibition of A431 tumor growth in athymic mice [1]. SU6668 (75 mg/kg/day; i.p. for 22 d) significantly inhibits tumor angiogenesis and vascularization in mice [1]. SU6668 (200 mg/kg/day; p.o. for 11-27 d) induces striking regression of large established A431 xenografts in athymic mice [1]. Animal Model: Female athymic mice (BALB/c, nu/nu ) were implanted A431 tumor cells [1] Dosage: 4, 40, 75, 200 mg/kg Administration: P.o. daily for 21 days Result: Induced 97% growth inhibition against A431 tumor at the dose of 97%. No mortality was observed in any treatment group. |
分子量 | 310.35 |
分子式 | C18H18N2O3 |
CAS No. | 210644-62-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(Z)-Orantinib 210644-62-5 (Z) Orantinib Orantinib (Z)Orantinib Inhibitor inhibitor inhibit